Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for Prevention of Chronic Migraine
NCT03855137Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of atogepant in chronic migraine (3 arms), sponsored by Allergan. Primary endpoint: Change From Baseline in Mean Monthly Migraine Days at 12 weeks. Started Mar 2019; status: completed.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03855137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855137.